加巴喷丁治疗转移性前列腺腺癌所致癌痛爆发的疗效评估。
Evaluation of Gabapentin as a Treatment of Breakthrough Cancer Pain Caused by Metastatic Prostate Adenocarcinoma.
作者信息
Ismy Jufriady, Emril Dessy R, Khalilullah Said Alfin, Mauny Muhammad Puteh
机构信息
Department of Urology, Faculty of Medicine, Universitas Syiah Kuala/Dr. Zainoel Abidin General Hospital, Aceh, Indonesia.
Department of Neurology, Faculty of Medicine, Universitas Syiah Kuala/Dr. Zainoel Abidin General Hospital, Aceh, Indonesia.
出版信息
J Pain Res. 2023 Oct 2;16:3319-3324. doi: 10.2147/JPR.S422769. eCollection 2023.
INTRODUCTION
Breakthrough Cancer Pain (BTcP) is defined as a temporary increase in pain that occurs spontaneously. The use of gabapentin is believed to be able to reduce pain complaints in patients with BTcP. However, research to support the efficacy of gabapentin in relieving pain in patients with BTcP is still limited. This study aims to determine the effectiveness of the use of gabapentin in patients with BTcP caused by metastatic prostate adenocarcinoma.
METHODS
The study was conducted by analytic study with a prospective approach. The subjects were all patients with metastatic prostate adenocarcinoma at Zainoel Abidin General Hospital during 2022-2023 which fulfilled inclusion and exclusion criteria (30 patients). Data analysis was performed in the form of reduction in pain scale in patients with BTcP caused by metastatic prostate adenocarcinoma using gabapentin and the combination of the opioid gabapentin with -Test.
RESULTS
The results showed that there was no significant difference between the reduction in posttreatment pain in patients with BTcP caused by metastatic prostate adenocarcinoma taking gabapentin alone or taking the opioid gabapentin combination, either on days 3-4 or on days 5-6 (p > 0.05). However, based on the results of the evaluation on day 3-4, it was found that gabapentin was able to reduce pain by 2.2272, whereas the combination of opioid gabapentin was only able to reduce pain by 1.916. The evaluation on days 5-6 showed that gabapentin was able to reduce pain by 4.1363 and the combination of gabapentin opioids by 3.2083.
CONCLUSION
The conclusion of this research is that gabapentin is effective in the treatment of BTcP caused by metastatic prostate adenocarcinoma.
引言
突破性癌痛（BTcP）被定义为自发出现的疼痛暂时加剧。据信，加巴喷丁的使用能够减轻BTcP患者的疼痛主诉。然而，支持加巴喷丁缓解BTcP患者疼痛疗效的研究仍然有限。本研究旨在确定加巴喷丁对转移性前列腺腺癌所致BTcP患者的有效性。
方法
本研究采用前瞻性分析研究方法。研究对象为2022年至2023年期间在宰努勒阿比丁综合医院符合纳入和排除标准的所有转移性前列腺腺癌患者（30例）。数据分析以使用加巴喷丁以及阿片类药物与加巴喷丁联合用药的转移性前列腺腺癌所致BTcP患者疼痛量表的降低情况的形式进行，并采用t检验。
结果
结果显示，单独服用加巴喷丁或服用阿片类药物与加巴喷丁联合用药的转移性前列腺腺癌所致BTcP患者，在治疗后第3至4天或第5至6天的疼痛减轻情况之间无显著差异（p>0.05）。然而，根据第3至4天的评估结果，发现加巴喷丁能够使疼痛减轻2.2272，而阿片类药物与加巴喷丁联合用药仅能使疼痛减轻1.916。第5至6天的评估显示，加巴喷丁能够使疼痛减轻4.1363，阿片类药物与加巴喷丁联合用药能使疼痛减轻3.2083。
结论
本研究的结论是，加巴喷丁对转移性前列腺腺癌所致BTcP有效。
Zotero 插件